
Gilead Science's remdesivir manufacturing projections 2020
As of July 2020, American biopharmaceutical company Gilead Sciences expected that they will produce more than two million treatment courses of their antiviral drug remdesivir by the end of the year in order to meet the global real-time need. This statistic depicts the cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020.